LivsMed KRX:491000KOSDAQ
리브스메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked20since Sep 11
In Q2 2026, LivsMed reported revenue of ₩12.5bn, up 9.6% year on year, and an operating loss of ₩12.2bn. LivsMed (리브스메드) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 3 articles.
Filing signals 4 quarters of losses Screener
LivsMed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩12.5bn | +9.6% | −₩12.2bn margin −97.5% | −₩11.0bn |
| Q1 2026 | ₩10.3bn | +5.5% | −₩8.4bn margin −81.5% | −₩5.9bn |
| Q2 2025 | ₩11.4bn | – | −₩5.4bn margin −47.6% | −₩6.9bn |
| Q1 2025 | ₩9.7bn | – | −₩6.7bn margin −68.4% | −₩6.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
LivsMed top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6